Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.42 |
| ▸ | FURIN | P09958 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2414756 | 0.98 | PARP10 (0.48) | PARP10HPGDALDH1A1TSHRHRH3 | |
| SCHEMBL9966865 | 0.93 | PARP10 (0.53) | PARP10HPGDALDH1A1TSHRHRH3 | |
| Hydrochloric Acid SCHEMBL30522774 | 0.91 | PARP10 (0.52) | PARP10HPGDALDH1A1TSHRHRH3 | |
| SCHEMBL835805 | 0.89 | EPHX2 (0.49) | PARP10ALDH1A1TSHRHRH3EPHX2 | |
| SCHEMBL2242868 | 0.89 | PARP10 (0.55) | PARP10HPGDALDH1A1TSHRHRH3 | |
| SCHEMBL16561564 | 0.86 | PARP10 (0.57) | PARP10ALDH1A1EPHX2MAPT | |
| SCHEMBL23410183 | 0.81 | HRH1 (0.58) | PARP10HRH3 | |
| SCHEMBL29995412 | 0.81 | HRH1 (0.58) | PARP10HRH3 | |
| SCHEMBL623629 | 0.80 | PARP10 (0.53) | PARP10HPGDALDH1A1TSHRHRH3 | |
| SCHEMBL2016296 | 0.79 | EPHX2 (0.43) | PARP10HPGDALDH1A1TSHRHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115215923-B | Macrocyclic broad-spectrum antibiotics | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20250059176-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2025-02-20 | — | — | US | disclosed |
| US-12162873-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2024-12-10 | — | — | US | disclosed |
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-31 | — | — | US | disclosed |
| US-20240101545-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| CN-112204029-B | Therapeutic compounds | 豪夫迈·罗氏有限公司 | 2024-03-01 | — | — | CN | disclosed |
| EP-4289480-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | F. Hoffmann-La Roche AG (CH) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289480-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | F. Hoffmann-La Roche AG (CH) | 2023-12-13 | — | — | EP | disclosed |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | Guangzhou Innocare Pharma Tech Co., Ltd (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | Guangzhou Innocare Pharma Tech Co., Ltd (CN) | 2023-12-12 | — | — | US | disclosed |
| WO-2009143051-A1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-6958402-B2 | 3-(imidazolyl)-2-alkoxypropanoic acids | PFIZER, INC. (US) | 2005-10-25 | — | — | US | disclosed |
| US-20040254164-A1 | 3-(imidazolyl)-2-alkoxypropanoic acids | PFIZER INC. (US) | 2004-12-16 | — | — | US | disclosed |
| EP-1467731-A1 | 3-(IMIDAZOLYL)-2-ALKOXYPROPANOIC ACIDS AS TAFIA INHIBITORS | Pfizer Limited (GB) | 2004-10-20 | — | — | EP | disclosed |
| CN-1157376-C | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and drugs containing the same | ��һ��������ҩ��ʽ���� | 2004-07-14 | — | — | CN | disclosed |
| US-6713496-B2 | 3-(imidazolyl)-2-alkoxypropanoic acids | PFIZER INC | 2004-03-30 | — | — | US | disclosed |
| US-20030199522-A1 | 3-(Imidazolyl)-2-alkoxypropanoic acids | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2003061652-A1 | 3-(IMIDAZOLYL)-2-ALKOXYPROPANOIC ACIDS AS TAFIA INHIBITORS | PFIZER LIMITED (GB) | 2003-07-31 | — | — | WO | disclosed |
| CN-1246110-A | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and drugs containing the same | SUNTORY LTD (JP) | 2000-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199522-A1 | 3-(Imidazolyl)-2-alkoxypropanoic acids | F2, FGB, F7 | PARP10 2598/4885HPGD 1000/4885ALDH1A1 191/4885 |
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | PARP10 3856/4885HPGD 889/4885ALDH1A1 177/4885 |
| US-20250059176-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | BTK, SYK, LYN | PARP10 741/4885HPGD 1040/4885ALDH1A1 3301/4885 |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | ABL1, TPMT, CYP2C19 | PARP10 1803/4885HPGD 1283/4885ALDH1A1 292/4885 |
| US-20040254164-A1 | 3-(imidazolyl)-2-alkoxypropanoic acids | F2, FGB, F7 | PARP10 2606/4885HPGD 950/4885ALDH1A1 217/4885 |
| US-20240101545-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | BTK, SYK, LYN | PARP10 741/4885HPGD 1040/4885ALDH1A1 3301/4885 |
| US-12162873-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | BTK, SYK, LYN | PARP10 741/4885HPGD 1040/4885ALDH1A1 3301/4885 |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | BTK, SYK, LYN | PARP10 741/4885HPGD 1040/4885ALDH1A1 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.